{
    "clinical_study": {
        "@rank": "109157", 
        "arm_group": [
            {
                "arm_group_label": "Bimatoprost Solution BID", 
                "arm_group_type": "Experimental", 
                "description": "Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months."
            }, 
            {
                "arm_group_label": "Bimatoprost Solution QD", 
                "arm_group_type": "Experimental", 
                "description": "Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months."
            }, 
            {
                "arm_group_label": "Vehicle to Bimatoprost Solution BID", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of  bimatoprost solution  compared with\n      vehicle in the treatment of eyebrow hypotrichosis (inadequate eyebrows)."
        }, 
        "brief_title": "Bimatoprost for the Treatment of Eyebrow Hypotrichosis", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Eyebrow Hypotrichosis", 
        "condition_browse": {
            "mesh_term": "Hypotrichosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Mild to moderate eyebrow hypotrichosis (inadequate eyebrows)\n\n        Exclusion Criteria:\n\n          -  Patients with disease, infection, or abnormality of the eyebrow area\n\n          -  Patients with permanent eyebrow loss due to over-grooming"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "357", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765764", 
            "org_study_id": "192024-043"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Bimatoprost Solution BID", 
                    "Bimatoprost Solution QD"
                ], 
                "description": "Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.", 
                "intervention_name": "bimatoprost solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Bimatoprost Solution QD", 
                    "Vehicle to Bimatoprost Solution BID"
                ], 
                "description": "Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.", 
                "intervention_name": "Vehicle to bimatoprost solution", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "3", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Participants with at Least a 1-grade Increase (improvement) in the 4-point Global Eyebrow Assessment (GEBA) Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Month 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 7"
            }, 
            {
                "measure": "Change from Baseline in Eyebrow Darkness as Measured Using DMSIA", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 7"
            }, 
            {
                "measure": "Percentage of Participants with 'Very Satisfied' or 'Mostly Satisfied' in Eyebrow Satisfaction Scale (ESS) Item #6", 
                "safety_issue": "No", 
                "time_frame": "Month 7"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}